{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:01:25Z","timestamp":1785214885804,"version":"3.55.0"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1055\/a-2696-8438","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:32:30Z","timestamp":1785191550000},"page":"822-827","source":"Crossref","is-referenced-by-count":0,"title":["Immuntherapie-induzierte Nebenwirkungen: Im Brennpunkt der Intensivmedizin"],"prefix":"10.1055","volume":"151","author":[{"given":"Boris","family":"B\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Garcia Borrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Grans-Siebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e4cilia","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"BJ Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"L Khoja","year":"2017","journal-title":"Annals of Oncology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis","volume":"5","author":"Y Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"A Farina","year":"2024","journal-title":"The Lancet Neurology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3390\/jcm15020814","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact","volume":"15","author":"A Mauriello","year":"2026","journal-title":"Journal of Clinical Medicine"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","article-title":"Immune Checkpoint Inhibitor\u2013Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement","volume":"12","author":"J Herrmann","year":"2026","journal-title":"JAMA Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"JR Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007409","article-title":"Corticosteroid-resistant immune-related adverse events: a systematic review","volume":"12","author":"E Daetwyler","year":"2024","journal-title":"J Immunother Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114028","article-title":"Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"203","author":"T Ruf","year":"2024","journal-title":"European Journal of Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102936","article-title":"From ICI to ICU: A systematic review of patients with solid tumors who are treated with immune checkpoint inhibitors (ICI) and admitted to the intensive care unit (ICU)","volume":"136","author":"B Dijk","year":"2025","journal-title":"Cancer Treatment Reviews"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/onco.13740","article-title":"Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018","volume":"26","author":"GE Molina","year":"2021","journal-title":"Oncologist"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1158\/1078-0432.CCR-24-2990","article-title":"Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer","volume":"31","author":"F Pecci","year":"2025","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"X Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells","volume":"25","author":"DW Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following CAR-T cell therapy: A Systematic Review","volume":"28","author":"SJ Grant","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR-T Cell-Associated Neurotoxicity","volume":"11","author":"J Gust","year":"2020","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s00108-025-01944-y","article-title":"Nebenwirkungsmanagement bei CAR-T-Zellen","volume":"66","author":"F Bach","year":"2025","journal-title":"Innere Medizin"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"MR Hines","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"CE Graham","year":"2025","journal-title":"The Lancet Oncology"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2696-8438.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:46:33Z","timestamp":1785213993000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2696-8438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2696-8438","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}